Rivaroxaban Versus Warfarin in Patients With Atrial Fib
America: Insights From ROCKET AF

American Heart Journal

236, 4-12

DOI: 10.1016/j.ahj.2021.02.004

Citation Report

#	Article	IF	Citations
1	Direct Oral Anticoagulants vs. Warfarin in Latin American Patients With Atrial Fibrillation: Evidence From Four Post-Hoc Analyses of Randomized Clinical Trials. Frontiers in Cardiovascular Medicine, 2022, 9, 841341.	3.2	0
2	Plasma Rivaroxaban Level in Patients With Early Stages of Chronic Kidney Disease—Relationships With Renal Function and Clinical Events. Frontiers in Pharmacology, 2022, 13, 888660.	5.3	10
3	Efficacy and Safety of Different Dosing Regimens of Rivaroxaban in Patients With Atrial Fibrillation for Stroke Prevention: A Systematic Review and Meta-Analysis. Cureus, 2024, 16, e51541.	1.3	3
4	Assessing the Safety and Efficacy of Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation: A Systemic Review and Meta-Analysis. Cureus, 2024, 16, e54252.	1.3	0